PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
Viroporins
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
CXCR4
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

Lysostaphin

PSI-SGKB [doi:10.3942/psi_sgkb/fm_2009_7]
Featured System - July 2009
Short description: Antibiotics are one of the major triumphs of twentieth century science, but unfortunately, the bacteria are fighting back.

Antibiotics are one of the major triumphs of twentieth century science, but unfortunately, the bacteria are fighting back. Drug-resistant strains are continually emerging as bacteria evolve and share new methods to shield their antibiotic-sensitive machinery, or destroy antibiotics directly. Today, we are searching for new approaches to fight our microscopic enemies using the tools of structural and molecular biology.

Magic Bullets

As with much of the earliest work in antibiotic discovery, researchers at the NYSGXRC are looking to the microbial world for leads. They have recently solved the structure of lysostaphin from the bacterium Vibrio cholerae. Like lysozyme, the original magic bullet explored by Alexander Fleming, lysostaphin is an enzyme that attacks the cell walls of bacteria. These cell walls are composed of long strings of sugars and amino acids, which are then crosslinked into a tough network that encloses the cell. Lysozyme and lysostaphin break linkages in this peptidoglycan network, and the cells burst under their own internal pressure.

Targeted Attack

Lysostaphin is a specialized killer, however. The crosslinks in the peptidoglycan come in many varieties. In some bacteria, the links are formed directly between amino acids in the peptidoglycan strands. In Staphylococcus aureus, however, a strand of five glycine amino acids is used as the linker. This is the weak point that is targeted by lysostaphin--it binds to the peptidoglycan sheath and clips these glycine crosslinkers.

Battling Infection

Lysostaphin is currently being tested as a possible treatment for infections by Staphylococcus infections. This includes topical formulations for treatment of infected wounds, as well as systemic formulations used in combination with antibiotics. Lysostaphin has been shown to be effective against antibiotic-resistant forms of the bacteria. But as with all interactions with bacteria, there is still the potential that they will develop ways to overcome it. Already, strains have been discovered that are less susceptible to lysostaphin, strains that either build a gluey polysaccharide capsule that shields their peptidoglycan, or strains that fortify the linkers in their peptidoglycan. The battle continues...

The JSmol tab below displays an interactive JSmol.

VapBC-5 Toxin-Antitoxin (PDB entry 3dbo)

The toxin is shown in pink and the antitoxin is shown in blue. Three water molecules, shown here in turquoise, are bound in the presumed active site, coordinated by a cluster of acidic amino acids, shown here in brighter red. These are thought to be the sites that bind to magnesium in the active enzyme. Use the buttons below to display or hide the antitoxin.

References

  1. Ragumani, S., Kumaran, D., Burley, S. K. and Swaminathan, S. (2008) Crystal structure of a putative lysostaphin peptidase from Vibrio cholerae. Proteins 72, 1096-1103.
    Kumar, J. K. (2008) Lysostaphin: an antistaphylococcal agent. Appl. Microbiol. Biotechnol. 80, 555-561.

  2. Firczuk, M., Mucha, A. and Bochtler, M. (2006) Crystal structures of active LytM. J. Mol. Biol. 354, 578-590.

  3. Bochtler, M., Odintsov, S. G., Marcyjaniak, M. and Sabala, I. (2004) Similar active sites in lysostaphins and D-Ala-D-Ala metallopeptidases. Prot. Sci. 13, 854-861.

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health